Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2006

View Archived Issues

Preclinical and clinical efficacy and safety of MB-06322 in type 2 diabetes

CHIR-258 continues clinical development

BTG to begin U.S. phase II study for Varisolve

Synthetic Blood International signs Mexican letter of intent for Oxycyte trial

Innate Pharma strengthens TLR platform

Bio-Bridge Science reports preclinical findings from oral HIV vaccine

SPA for registrational metastatic melanoma trial of ipilimumab plus chemotherapy

GTI-2040 to be studied in MDS and AML

Cognate Therapeutics changes name to Cognate BioServices

Phase II study of IR-103 in HIV patients cleared for expansion

PharmaFrontiers changes name to Opexa Therapeutics

Positive results reported for Exubera inhaled insulin

Panflu induces immune response in healthy volunteers

Postoperative MAGE-A3 vaccine well tolerated in NSCLC

Cytokinetics and GSK extend research collaboration

Phase I and II studies evaluate AIR inhaled insulin system

Toray granted Japanese license to AC-200

Neurodex NDA review period extended

Oxybate improves fibromyalgia symptoms

Phase II studies reveal nilotinib activity in hematological malignancies

MT-103 active in non-Hodgkin's lymphoma

Clazosentan reduces occurrence of cerebral vasospasm in study

Avastin approved for second-line use in metastatic colorectal cancer

Cognition improvement by novel alpha7 nAChR partial agonist in rats

Recent Janssen and Zambon patents report novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Novel dopamine D3 receptor antagonists for drug dependence emerge from Bioprojet R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...